



Ami Organics Limited

CIN. : L24100GJ2007PLC051093

Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India.

May 2, 2025

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

Scrip Code: 543349

NSE Symbol: AMIORG

Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release discussing the fourth quarter & year ended financial results as on March 31, 2025.

This Press Release will be available on the website of the Company www.amiorganics.com.

Kindly take the same on record.

Yours faithfully,
For, AMI ORGANICS LIMITED



Ekta Kumari Srivastava
Company Secretary & Compliance Officer

Encl: Press Release





Ami Organics Limited reports Q4 & FY25 Results

FY25 Delivers Strong Growth: Revenue at ₹1,007 Cr, up 40.3% YoY

FY25 EBITDA Margin Expanded by 514bps YoY to 23.0%

Surat, May 02, 2025: Ami Organics Limited (AMI) (BSE: 543349, NSE: AMIORG), a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, today announced financial results for the quarter and year ended March 31, 2025.

Consolidated Financial Results – Q4 & FY25:

Particulars (Rs. Mn)	Q4FY25	Q4FY24	YoY	Q3FY25	QoQ	FY25	FY24	YoY
Revenue from Operations	3,085	2,250	37.1%	2,750	12.2%	10,069	7,175	40.3%
Gross Profit	1,460	900	62.3%	1,272	14.8%	4,547	3,058	48.7%
Gross Margin	47.3%	40.0%		46.2%		45.2%	42.6%	
EBITDA	850	432	96.8%	687	23.7%	2,321	1,285	80.6%
EBITDA Margin	27.5%	19.2%		25.0%		23.0%	17.9%	
PAT	627	257	144.2%	454	38.0%	1,604	808	98.6%
PAT Margin	20.3%	11.4%		16.5%		15.9%	11.3%	

Note: FY24: PAT and PAT Margin are adjusted for Exceptional Items.

Commenting on results, Mr. Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said: *“I am delighted to share that FY25 was a transformative year for Ami Organics, as we proudly surpassed ₹1,000 crore in revenue—a remarkable milestone. This achievement reflects the unwavering dedication of our employees and the invaluable support of our stakeholders, including customers, suppliers, shareholders and all other stakeholders. We extend our heartfelt gratitude for their contributions.*

As we embark on an exciting new phase of growth, we are embracing a bold, future-focused brand identity that aligns with our vision to lead as a diversified specialty chemicals company, serving next-generation industries with a steadfast commitment to sustainability. To reflect this ambition, we are transitioning from “Ami Organics Limited” to “Acutaas Chemicals Limited”.

Looking ahead to FY26, we anticipate robust growth across all business segments, driving our confidence in achieving 25% revenue growth.”



Key Results & Business Highlights (Q4FY25 Consolidated):

- ✓ **Revenue from operations** for Q4FY25 grew by **37.1% YoY to Rs. 3,085 mn**
- ✓ The **gross margin** for the quarter improved to **47.3%** up 734 bps YoY and 108 bps QoQ
- ✓ **EBITDA** for the quarter came at **Rs. 850 mn** up 96.8% YoY compared to Rs. 432 mn in Q4FY24.
- ✓ **EBITDA margin** for the quarter was at **27.5%** as compared to 19.2% in Q4FY24.
- ✓ **PAT** for the quarter was **Rs. 627 mn** up 144.2% as compared to PAT of Rs. 257 mn in Q4FY24
- ✓ The **PAT margin** for the quarter was at **20.3%** up 892 bps YoY and 380 bps QoQ
- ✓ Export for the quarter at **74%**; domestic business at **26%**

ABOUT AMI ORGANICS LIMITED:

Ami Organics, headquartered at Surat, is a research and development (“R&D”) driven manufacturer of speciality chemicals focused towards the development and manufacturing of advanced pharmaceutical intermediates (“Pharma Intermediates”) for regulated and generic active pharmaceutical ingredients (“APIs”) and chemicals for New Chemical Entities (“NCE”), and other specialty chemicals including parabens and paraben formulations, methyl salicylate, semiconductor chemicals, electrolyte additives and niche key starting materials (“KSM”) for cosmetics, fine chemicals and agrochemical industries.

The Pharma Intermediates, find application in certain high-growth therapeutic areas including anti-depressant, anti-cancer, anti-retroviral, anti-Parkinson, and seizure disorder. Ami Organics is the market leader for various key intermediates across the globe and the first company in India outside of China to spearhead the pioneering development of electrolyte additives on a global scale.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Ami Organics has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

PRESS RELEASE

For Immediate dissemination



For details, please contact:

Investor Relations at Ami Organics

Ekta Srivastava, Company Secretary &
Compliance Officer

cs@amiorganics.com

Senior Manager – Investor Relations

Mr. Rahul Thakur

Rahul.thakur@amiorganics.com

Registered Office

Plot no. 440/4, 5 & 6, Road No. 82/A,
GIDC Sachin, Surat- 394230

CIN: L24100GJ2007PLC051093

ISIN: INE00FF01017

NSE Code: AMIORG

BSE CODE: 543349

Website: www.amiorganics.com